DaVita (DVA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

DaVita

NYSE•Healthcare•Medical Care Facilities

$183.09-10.77(-0.06%)Pre-market

Market Cap

$12.44B

P/E

14.7x

P/S

0.9x

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

How this company scores

WeakMetricSide Score: 62/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (8/25).

Profitability12/25

Growth17/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowStrong marginsCash-backed earningsConsistent free cash flow

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 14.7x5y range 9.2x – 19.2x

Currently near its 20-quarter median.

P/S · 0.9x5y range 0.6x – 1.1x

Currently near its 20-quarter median.

P/B · 100.9x5y range 7.2x – 100.9x

Currently above its 14-quarter median.

Price & Volume

Market Cap $12.44B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $14.01B
Q. Revenue: $3.55B
TTM EBITDA: $2.84B
TTM Op. Income: $2.13B
Q. Op. Income: $579.00M
TTM Net Income: $847.48M
Q. Net Income: $265.40M
EPS: $4.1
Shares Out.: $64.78M

$14.01B in TTM revenue grew 6.4% YoY, reaching $3.55B last quarter. TTM EBITDA of $2.84B and TTM operating income of $2.13B show growth is flowing through to the bottom line. TTM net income of $847.48M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 21.0%
Op. Margin: 16.3%
Net Margin: 7.5%

Op. margin of 16.3% is up 0.4% YoY — cost efficiency is improving. Net margin at 7.5% Over the past year, operating margin is up 2% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 14.7x
P/S Ratio: 0.9x
P/B Ratio: N/A

At 14.7x P/E, the stock trades below typical market levels. P/S of 0.9x and P/B of 0.0x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $17.71B
Cash: $668.96M
Long-Term Debt: $10.66B
Book Value: $-765.10M
D/E Ratio: N/A
Debt/EBITDA: 14.3

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $490.07M
TTM Free Cash Flow: $1.61B
FCF Margin: 11.5%
FCF / Net Income: 1.9

TTM FCF of $1.61B on $490.07M in operating cash flow. The FCF / Net Income ratio of 1.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.